Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open- angle glaucoma

American Journal of Ophthalmology

Volumn 128, Issue 1, 1999, Pages 15-20

  Konstas, Anastasios G P ^a   Maltezos, Athanasios C ^a   Gandi, Sofia ^a   Hudgins, Alison C ^b   Stewart, William C ^b,c  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b University of South Carolina   (United States)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LATANOPROST; TIMOLOL MALEATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DOSE CALCULATION; DRUG EFFICACY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; OPEN ANGLE GLAUCOMA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RETINA PIGMENT EPITHELIOPATHY; TONOMETRY; TREATMENT OUTCOME;

EID: 0032977714     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(99)00073-2     Document Type: Article

References (13)

1. Nilsson S.F.E., Samuelsson M., Bill A., Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2±-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 48:1989;707.
2. Watson P., Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 103:1996;126-137.
3. Mishima H.K., Masuda K., Kitazawa Y., Azuma I., Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. Arch Ophthalmol. 114:1996;929-932.
4. Alm A., Stjernschantz J. Effects on intraocular pressure and side-effects of 0.005% latanoprost applied once daily, evening or morning a comparison with timolol . Ophthalmology. 102:1995;1743-1752.
5. Camras C.B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma a six-month, masked, multicenter trial in the United States . Ophthalmology. 103:1996;138-147.
6. Summary basis of approval for Xalatan. US FDA Medical Offices Reviews NDA#20-597 Rev. Feb 12, 1996:49-51.
7. Stewart W.C. Clinical practice of glaucoma. 1990;SLACK, Inc, Thorofare, New Jersey.
8. Konstas A.G.P., Mantziris D.A., Cate E.A., Stewart W.C. Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma. Arch Ophthalmol. 115:1997;975-979.
9. Neter J., Wasserman W., Kutner M.H. Analysis of covariance applied lineal statistical models . 1985;844-873 Richard D. Irvin, Inc, Illinois.
10. Book S.A. Essentials of statistics. 1978;McGraw Hill Book Company, New York.
11. Hotehama Y., Mishima H.K., Kitazawa Y., Masuda K. Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary open-angle glaucoma. Jpn J Ophthalmol. 37:1993;270-274.
12. Shields M.B. Textbook of glaucoma. 1982;Williams and Wilkins, Maryland.
13. Stewart W.C., Castelli W.P. Systemic side effects of topical β-adrenergic blockers. Clin Cardiol. 19:1996;691-697.